# Treatment methods for liver cancer
The treatment of liver cancer is determined by the size and number of tumors, the condition of the liver itself, how far the disease has progressed, and the patient's overall health. Various approaches are possible, often in combination: surgical removal, local heating or numbing of the tumor, targeted drugs, immunotherapy, and radiation. This overview describes what these treatments involve and how they work.
Surgical removal (resection)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For liver cancer that is confined to a small part of the liver, and where enough healthy liver tissue remains, surgical removal of the affected area may be considered. The surgeon removes the tumor together with a zone of healthy tissue around it.
*How it works:* This is the only treatment that can completely remove the tumor, but is only possible when the liver still has sufficient function and the cancer has not spread too far.
*Side effects:* Blood loss, infection, bile duct leakage, and temporarily reduced liver function are possible risks. The liver can recover and regenerate, but this takes time. Pain and fatigue after the procedure are common.
Liver transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
When the cancer is small and limited, but the liver is severely damaged by cirrhosis, complete replacement of the damaged liver with a donor liver may be an option. This is only done under strict criteria.
*How it works:* The diseased liver is completely removed and replaced with a healthy liver from a donor. This removes both the cancer and the underlying liver disease.
*Side effects:* Rejection reactions require lifelong immunosuppressants (medicines that suppress the immune system). Side effects of these can include infections, kidney problems, and other conditions. Availability of donor organs is limited.
Radiofrequency ablation (RFA)
ProveniIncluded in official guidelines, or approved by EMA or FDA
Radiofrequency ablation uses heat waves to kill cancer cells directly. A needle is guided through the skin to the tumor (possibly under ultrasound or CT guidance) and heats the tissue until it dies.
*How it works:* Electrical energy heats the tumor area to approximately 60–90 °C, causing cell death.
*Side effects:* Burns around the tumor (intra-abdominal damage), infection, and local pain are possible. For tumors just below the surface, skin burns may occur. Bleeding and gallbladder damage are rare but documented.
Microwave ablation
ProveniIncluded in official guidelines, or approved by EMA or FDA
Similar to radiofrequency, but microwave ablation works via magnetic fields that build up heat faster. It can be applied in multiple locations at once.
*How it works:* Microwaves heat the tumor tissue faster than radiofrequency, which can be advantageous for larger tumors or those with more blood flow.
*Side effects:* Similar to RFA: heat damage to surrounding healthy tissue, infection, pain, and rarely serious complications such as gallbladder damage or bleeding.
Transarterial chemoembolization (TACE)
ProveniIncluded in official guidelines, or approved by EMA or FDA
TACE delivers chemotherapy directly into the artery that feeds the tumor, and then blocks this blood flow with fine particles. This way, the tumor receives toxic substance at high concentration without burdening the rest of the body.
*How it works:* Via a catheter in the groin, the chemotherapy with blood-blocking materials is sent to the tumor artery. Without blood supply, tumor tissue dies.
*Side effects:* Pain, nausea, fever, and in some cases damage to healthy liver tissue. Kidney problems may occur. Post-embolization syndrome (pain, fever) is common and temporary.
Sorafenib and other tyrosine kinase inhibitors
ProveniIncluded in official guidelines, or approved by EMA or FDA
These pill medications inhibit proteins that drive cancer growth. Sorafenib is the standard targeted therapy for advanced liver cancer, even when surgery is not possible.
*How it works:* It blocks signals that tumor cells need to grow and divide. It also inhibits new blood vessel formation around the tumor.
*Side effects:* Diarrhea, fatigue, foot pain (hand-foot syndrome), skin rash, elevated blood pressure, and bleeding. Liver function may worsen. These side effects are frequent and require ongoing monitoring.
*Recent signal:* Other tyrosine kinase inhibitors are being investigated and applied, sometimes with better tolerability per patient.
Atezolizumab + bevacizumab (Imfinzi + Avastin)
ProveniIncluded in official guidelines, or approved by EMA or FDA
This combination links immunotherapy (atezolizumab) with an agent that counteracts blood vessels in the tumor (bevacizumab). It is standard in many countries for advanced liver cancer.
*How it works:* Atezolizumab helps the immune system recognize and attack tumor cells. Bevacizumab inhibits the blood supply to the tumor, which slows growth.
*Side effects:* Fatigue, elevated blood pressure, protein excretion in urine, bleeding, and immune-related inflammation (pneumonia, liver inflammation, bowel inflammation) can occur. Severe side effects may require treatment discontinuation.
*Recent signal:* This regimen offers benefit over sorafenib alone for patients with certain characteristics and stages.
Nivolumab + ipilimumab
ProveniIncluded in official guidelines, or approved by EMA or FDA
Two immune checkpoint inhibitors together. Nivolumab and ipilimumab are both given intravenously and work in different ways to deploy the immune system against the tumor.
*How it works:* Nivolumab blocks PD-1, ipilimumab blocks CTLA-4; both are 'brakes' on immune cells. Removing the block allows these cells to attack vigorously.
*Side effects:* Immune-related side effects can be severe: pneumonia, liver inflammation, bowel inflammation, skin conditions, thyroid problems. Fatigue and fluid accumulation are also frequent. Ongoing monitoring is needed.
Pembrolizumab (Keytruda)
ResearchediPositive results in clinical studies, not yet standard treatment
Pembrolizumab is a PD-1 inhibitor being investigated as monotherapy and in combination with other agents for liver cancer. Its role is still evolving.
*How it works:* Like nivolumab: it blocks PD-1 and allows immune cells to attack the tumor.
*Side effects:* Immune-related inflammation such as with nivolumab, though the profile may differ per patient. This approach is also being studied in combination with small molecules.
*Recent signal:* New combinations with pembrolizumab and anti-TIGIT agents (such as dual immune checkpoint blockade) are being studied for patients who have had immunotherapy without favorable effect.
Stereotactic body radiation therapy (SBRT)
ResearchediPositive results in clinical studies, not yet standard treatment
SBRT delivers very precise, powerful radiation beams to the tumor in a few sessions, with less damage to surrounding tissue. For liver cancer this is relatively new, but is increasingly combined with immunotherapy.
*How it works:* The radiation damages DNA in cancer cells, leading to cell death. Due to narrow beams, damage to healthy tissue is low.
*Side effects:* Fatigue, nausea, and in rare cases liver inflammation (radiation-induced liver disease) can occur. Damage can occur near vital organs.
*Recent signal:* Research indicates synergy between SBRT and immunotherapy: the radiation can help the immune system detect tumor cells.
Lenvatinib
ProveniIncluded in official guidelines, or approved by EMA or FDA
Lenvatinib is another tyrosine kinase inhibitor that proves comparable or sometimes better than sorafenib. It inhibits different protein pathways than sorafenib.
*How it works:* Similar to sorafenib: it inhibits growth signals and blood vessel formation, but acts on a different set of proteins.
*Side effects:* Diarrhea, cough, fatigue, elevated blood pressure, and kidney problems more often than sorafenib. Liver function must be monitored closely.
Regorafenib
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regorafenib is a tyrosine kinase inhibitor used in patients who no longer tolerate sorafenib or for whom it no longer works.
*How it works:* Blocks growth and blood vessels, via a slightly different mechanism than sorafenib.
*Side effects:* Hand-foot syndrome stronger than sorafenib, diarrhea, fatigue. Bleeding and liver problems are possible.
Trans-arterial radioembolization (TARE / radioembolization)
ResearchediPositive results in clinical studies, not yet standard treatment
TARE introduces radioactive beads (usually yttrium-90) into the artery that feeds the tumor. The radiation kills tumor cells and blocks nutrition at the same time.
*How it works:* Radioactive beads emit radiation directed at the tumor, while blood flow is reduced at the same time.
*Side effects:* Radiation-induced liver disease is the greatest risk, especially with an already damaged liver. Pain, nausea, and gastro-intestinal complications are possible.
*Recent signal:* TARE is increasingly used as a bridge: as first-line treatment or as preparation for immunotherapy or chemotherapy.
Experimental and combination approaches
ExperimentaliOngoing in study setting, outcome still unknown
Studies are looking at:
- Combinations of immunotherapy with local therapies (SBRT + immunotherapy, TACE + immunotherapy)
- New immune agents against hepatitis-B-specific T-cells
- Nanoparticles that strengthen immune response
- Local therapies with immune stimulators
These are not yet standard and are running as clinical trials.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._